BARD1 and prostate carcinoma: Then, we genotyped 5715 patients with unselected prostate cancer, and 10,252 cancer-free controls for three recurrent variants of BARD1 in the Polish population including one truncating variant (c.1690C>T; p.Q564X), one missense mutation (c.1972C>T; p.R658C), and one synonymous substitution (c.1977A>G; p.R659=).